These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 18585635

  • 1. [Bacillus of Calmette-Guérin immunotherapy: which protocol?].
    Saint F.
    Prog Urol; 2008 May; 18 Suppl 5():S99-104. PubMed ID: 18585635
    [Abstract] [Full Text] [Related]

  • 2. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder Group.
    Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
    [Abstract] [Full Text] [Related]

  • 3. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
    Böhle A, Bock PR.
    Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
    [Abstract] [Full Text] [Related]

  • 4. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED.
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up.
    Järvinen R, Kaasinen E, Rintala E, Group TF.
    Scand J Urol Nephrol; 2012 Dec; 46(6):411-7. PubMed ID: 22746387
    [Abstract] [Full Text] [Related]

  • 11. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.
    Cai T, Nesi G, Tinacci G, Zini E, Mondaini N, Boddi V, Mazzoli S, Bartoletti R.
    J Urol; 2008 Jul; 180(1):110-5. PubMed ID: 18485394
    [Abstract] [Full Text] [Related]

  • 12. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
    Andius P, Holmäng S.
    BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
    [Abstract] [Full Text] [Related]

  • 13. [Management of Ta, T1, and in situ bladder carcinoma: what is new?].
    Irani J.
    Prog Urol; 2008 May; 18 Suppl 5():S94-8. PubMed ID: 18585634
    [Abstract] [Full Text] [Related]

  • 14. Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: how much is enough?
    Decobert M, LaRue H, Harel F, Meyer F, Fradet Y, Lacombe L.
    Cancer; 2008 Aug 15; 113(4):710-6. PubMed ID: 18543328
    [Abstract] [Full Text] [Related]

  • 15. [Results of BCG in the treatment of pTa and pT1 bladder tumors. Evaluation of a long protocol using 75 mg of Pasteur strain BCG].
    Ayed M, Ben Hassine L, Ben Slama R, Chelbi N, Ghozzi S, Drissi H, Jemni M, Chebil M.
    Prog Urol; 1998 Apr 15; 8(2):206-10. PubMed ID: 9615929
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
    Ojea A, Nogueira JL, Solsona E, Flores N, Gómez JM, Molina JR, Chantada V, Camacho JE, Piñeiro LM, Rodríguez RH, Isorna S, Blas M, Martínez-Piñeiro JA, Madero R, CUETO Group (Club Urológico Español De Tratamiento Oncológico).
    Eur Urol; 2007 Nov 15; 52(5):1398-406. PubMed ID: 17485161
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.